Barbanoj MJ - Search Results

1

Rupatadine does not potentiate the CNS depressant effects of lorazepam: randomized, double-blind, crossover, repeated dose, placebo-controlled study.

García-Gea C, Ballester MR, Martínez J, Antonijoan RM, Donado E, Izquierdo I, Barbanoj MJ. García-Gea C, et al. Among authors: barbanoj mj. Br J Clin Pharmacol. 2010 Jun;69(6):663-74. doi: 10.1111/j.1365-2125.2010.03648.x. Br J Clin Pharmacol. 2010. PMID: 20565458 Free PMC article. Clinical Trial.

2

Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers.

Barbanoj MJ, García-Gea C, Antonijoan R, Izquierdo I, Donado E, Pérez I, Solans A, Jané F. Barbanoj MJ, et al. Hum Psychopharmacol. 2006 Jan;21(1):13-26. doi: 10.1002/hup.741. Hum Psychopharmacol. 2006. PMID: 16389668 Clinical Trial.

3

Comparison of inhibition of cutaneous histamine reaction of ebastine fast-dissolving tablet (20 mg) versus desloratadine capsule (5 mg): a randomized, double-blind, double-dummy, placebo-controlled, three-period crossover study in healthy, nonatopic adults.

Antonijoan R, García-Gea C, Puntes M, Pérez J, Esbrí R, Serra C, Fortea J, Barbanoj MJ. Antonijoan R, et al. Among authors: barbanoj mj. Clin Ther. 2007 May;29(5):814-822. doi: 10.1016/j.clinthera.2007.05.001. Clin Ther. 2007. PMID: 17697901 Clinical Trial.

4

No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelines.

Donado E, Izquierdo I, Pérez I, García O, Antonijoan RM, Gich I, Solans A, Peña J, Morganroth J, Barbanoj MJ. Donado E, et al. Among authors: barbanoj mj. Br J Clin Pharmacol. 2010 Apr;69(4):401-10. doi: 10.1111/j.1365-2125.2009.03599.x. Br J Clin Pharmacol. 2010. PMID: 20406224 Free PMC article. Clinical Trial.

5

Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments.

García-Gea C, Martínez-Colomer J, Antonijoan RM, Valiente R, Barbanoj MJ. García-Gea C, et al. Among authors: barbanoj mj. J Clin Psychopharmacol. 2008 Dec;28(6):675-85. doi: 10.1097/JCP.0b013e31818b2091. J Clin Psychopharmacol. 2008. PMID: 19011437 Clinical Trial.

6

A comparison of ebastine 10 mg fast-dissolving tablet with oral desloratadine and placebo in inhibiting the cutaneous reaction to histamine in healthy adults.

Antonijoan RM, García-Gea C, Puntes M, Valle M, Esbri R, Fortea J, Barbanoj MJ. Antonijoan RM, et al. Among authors: barbanoj mj. Clin Drug Investig. 2007;27(7):453-61. doi: 10.2165/00044011-200727070-00002. Clin Drug Investig. 2007. PMID: 17563125 Clinical Trial.

7

Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers.

Estévez JA, Moltó J, Tuneu L, Cedeño S, Antonijoan RM, Mangues MA, Clotet B, Domingo P, Puntes M, Barbanoj MJ, Valle M. Estévez JA, et al. Among authors: barbanoj mj. J Antimicrob Chemother. 2012 Aug;67(8):2013-9. doi: 10.1093/jac/dks152. Epub 2012 May 7. J Antimicrob Chemother. 2012. PMID: 22566588 Clinical Trial.

8

Comparative study on the bioequivalence of two different gabapentin formulations. A randomised, two-period, two-sequence, crossover clinical trial in healthy volunteers.

Almeida S, Filipe A, Almeida A, Antonijoan R, García-Gea C, Gich I, Barbanoj M, Cruz Caturla M. Almeida S, et al. Arzneimittelforschung. 2006;56(2):59-63. doi: 10.1055/s-0031-1296702. Arzneimittelforschung. 2006. PMID: 16572918 Clinical Trial.

9

Comparative study on the bioequivalence of two formulations of pravastatin. Data from a crossover, randomised, open-label bioequivalence study in healthy volunteers.

Almeida S, Filipe A, Almeida A, Gich I, Antonijoan R, Puntes M, Barbanoj M, Cruz Caturla M. Almeida S, et al. Arzneimittelforschung. 2006;56(2):70-5. doi: 10.1055/s-0031-1296704. Arzneimittelforschung. 2006. PMID: 16572920 Clinical Trial.

10

Sleep laboratory study on single and repeated dose effects of paroxetine, alprazolam and their combination in healthy young volunteers.

Barbanoj MJ, Clos S, Romero S, Morte A, Giménez S, Lorenzo JL, Luque A, Dal-Ré R. Barbanoj MJ, et al. Neuropsychobiology. 2005;51(3):134-47. doi: 10.1159/000085206. Epub 2005 Apr 18. Neuropsychobiology. 2005. PMID: 15838185 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

107 results

Search Page

Filters